Vanda Pharmaceuticals
VNDA
187 hedge funds and large institutions have $371M invested in Vanda Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 76 increasing their positions, 61 reducing their positions, and 11 closing their positions.
2,027% more call options, than puts
Call options by funds: $638K | Put options by funds: $30K
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
25% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 61
6% more funds holding
Funds holding: 177 → 187 (+10)
4.62% less ownership
Funds ownership: 102.55% → 97.93% (-4.6%)
6% less capital invested
Capital invested by funds: $396M → $371M (-$25.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.56M |
| 2 |
Goldman Sachs
New York
|
+$2.9M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$2.23M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.84M |
| 5 |
Man Group
London,
United Kingdom
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$8.28M |
| 2 |
Millennium Management
New York
|
-$7.58M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.35M |
| 4 |
EIP
Epoch Investment Partners
New York
|
-$4.8M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$3.83M |
VNDA Hedge Fund Activity: Q2 2023 in Review
187 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2023, worth a combined $371M — down 6.4% from $396M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VNDA positions and 11 closed out — a net gain of 10 holders — while 76 added to existing stakes and 61 trimmed.
The largest buyer was BlackRock, adding an estimated $4.56M. The largest seller was Bank of America, cutting an estimated $8.28M.
- 187 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2023, up from 177 in Q1 2023.
- Funds reported $371M of Vanda Pharmaceuticals stock for Q2 2023, down 6.4% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q2 2023 and 11 closed out, a net change of +10 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $4.56M added.
- The largest Vanda Pharmaceuticals seller in Q2 2023 was Bank of America, an estimated $8.28M sold.
Based on aggregated 13F filings for Q2 2023.